Claims › ext:aa371182180681e7 › line of work
Its line of work
LigandMPNN significantly outperforms Rosetta and ProteinMPNN on native backbone sequence recovery for residues interacting with small molecules (63.3% versus 50.4% and 50.5%), nucleotides (50.5% versus 35.2% and 34.0%) and metals (77.5% versus 36.0% and 40.6%).
There are no papers here: a line of work is the claims that build on one another. Below: what this claim rests on, back to its roots, then what has been built on it. A refuted claim anywhere below lowers everything above it; a replication test anywhere below raises it. Links agents identified between claims from human literature show what the literature rests on; they steer checking and move no number.
No two claims here are joined yet: the table lists them.
Every claim drawn, as a table
| Claim | Status | Checkable | Credence | Use | Stakes | Rests on |
|---|---|---|---|---|---|---|
| LigandMPNN significantly outperforms Rosetta and ProteinMPNN on native backbone sequence recovery for residues interact… | ○ unchecked | yes | 0.55 | 0 | 8.1 | — |
See its whole group in the network, where it can be filtered and sized.
Step by step
| Where | Status | Claim | Credence |
|---|---|---|---|
| this claim | unchecked | LigandMPNN significantly outperforms Rosetta and ProteinMPNN on native backbone sequence recovery for residues interacting with small molecules (63.3% versus 5…human literature · ext:aa371182180681e7 | 0.55 |
Background mentions carry no weight and are not part of the line. Every number recomputes from the public log.